Department of Radiology, Suining Central Hospital, Suining, Sichuan Province 629000, China.
Department of Medical Oncology, First Affiliated Hospital of Medical College of Shihezi University, Shihezi, Xinjiang Uygur Autonomous Region 832000, China.
J Immunol Res. 2018 Aug 2;2018:7498514. doi: 10.1155/2018/7498514. eCollection 2018.
Although aberrant expression of miR-34a, an essential tumor suppressor miRNA, has been frequently observed in colon cancer (CCa), whether miR-34a can regulate CCa progression by modulating other facets of this malignancy (such as multidrug resistance, MDR) remains unknown. Here, we report for the first time that miR-34a expression was significantly downregulated in clinical CCa samples from oxaliplatin-resistant patients and in experimentally established multidrug-resistant CCa cells. By using histoculture drug response assay, we further confirmed that clinical CCa samples with lower miR-34a expression appeared to be more resistant to chemotherapy. Functionally, ectopic expression of exogenous miR-34a resensitized multidrug-resistant HCT-8/OR cells to oxaliplatin treatment, whereas miR-34a inhibition augmented the oxaliplatin resistance in chemosensitive HCT-8 cells. Mechanistically, miR-34a positively regulated the mRNA stability of the ornithine decarboxylase antizyme 2 (OAZ2) by directly targeting its three prime untranslated region (3'UTR). Consequently, suppression of the expression of miR-34a/OAZ2 signaling by chemotherapeutic agents significantly enhanced the activation of MDR-associated ATP-binding cassette (ABC) transporters and antiapoptosis pathways, thus leading to MDR development in CCa cells. Collectively, our combined analysis reveals a critical role of miR-34a/OAZ2 cascade in conferring a proper cellular response to CCa chemotherapy.
尽管 miR-34a 的异常表达,作为一种必需的肿瘤抑制 miRNA,在结肠癌(CCa)中经常被观察到,但 miR-34a 是否可以通过调节这种恶性肿瘤的其他方面(如多药耐药性,MDR)来调节 CCa 的进展仍然未知。在这里,我们首次报道 miR-34a 的表达在奥沙利铂耐药患者的临床 CCa 样本和实验中建立的多药耐药性 CCa 细胞中显著下调。通过组织培养药物反应测定,我们进一步证实,miR-34a 表达较低的临床 CCa 样本似乎对化疗更具耐药性。功能上,外源性 miR-34a 的异位表达使多药耐药性 HCT-8/OR 细胞对奥沙利铂治疗重新敏感,而 miR-34a 抑制增强了化学敏感性 HCT-8 细胞对奥沙利铂的耐药性。从机制上讲,miR-34a 通过直接靶向其 3'非翻译区(3'UTR)来正向调节鸟氨酸脱羧酶抗酶 2(OAZ2)的 mRNA 稳定性。因此,化疗药物对 miR-34a/OAZ2 信号的表达抑制显著增强了多药耐药相关的 ABC 转运体和抗凋亡途径的激活,从而导致 CCa 细胞中多药耐药的发展。总的来说,我们的综合分析揭示了 miR-34a/OAZ2 级联在赋予 CCa 化疗适当的细胞反应中的关键作用。